Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α

The imidazolium compound Sepantronium Bromide (YM155) successfully promotes tumor regression in various pre-clinical models but has shown modest responses in human clinical trials. We provide evidence to support that the hypoxic milieu of tumors may limit the clinical usefulness of YM155. Hypoxia (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Danielpour, David, Corum, Sarah, Welford, Scott M., Shankar, Eswar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717246/
https://www.ncbi.nlm.nih.gov/pubmed/35005610
http://dx.doi.org/10.1016/j.crphar.2021.100076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717246/
https://www.ncbi.nlm.nih.gov/pubmed/35005610
http://dx.doi.org/10.1016/j.crphar.2021.100076

Ejemplares similares